This review of omalizumab use in chronic spontaneous urticaria (CSU) in Auckland City Hospital's immunology department in 2023 showed that rates of baseline investigations were high but did not clearly improve CSU management. There were associations between raised C-reactive protein and higher doses of omalizumab, and lower C-reactive protein and CSU remission. Most patients had angioedema and atopy. Median symptom duration was 5 years and the majority needed at least 1 year of omalizumab treatment. Fewer Māori/Pasifika patients in this cohort may reflect barriers to accessing health care.
Triffitt et al. (2026) studied this question.